Development of a new purified vero cell rabies vaccine (Rabivax-S) at the serum institute of India Pvt Ltd

Development of a new purified vero cell rabies vaccine (Rabivax-S) at the serum institute of India Pvt Ltd

Introduction: Rabies is a 100% fatal disease with significant disease burden in Asia and Africa but preventable with vaccines and immunoglobulins. There are very few WHO prequalified cell culture derived rabies vaccines available globally for use in humans. We have developed a new purified vero cell...

Full description

Bibliographic Details
Main Authors:	Prasad S. Kulkarni, Ashish Sahai, Bhagwat Gunale, Rajeev M Dhere
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2017-04-01
Series:	Expert Review of Vaccines
Subjects:	rabivax-s rabies purified vero cell rabies vaccine safety immunogenicity
Online Access:	http://dx.doi.org/10.1080/14760584.2017.1294068

Similar Items

Immunogenicity and safety of WHO-approved TRC-ID regimen with a chromatographically purified Vero cell rabies vaccine with or without rabies immunoglobulin in children
by: Piyada Angsuwatcharakon, et al.
Published: (2018-02-01)

Safety and immunogenicity of freeze-dried human rabies vaccines: A phase 3 clinical trial of Zagreb and Essen regimes
by: Jia Li, et al.
Published: (2024-12-01)

Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine
by: D.J. Briggs, et al.

Immunogenicity and safety of purified vero cell rabies vaccine (PVRV) produced by Liaoning Cheng Da Co. under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese adults aged 50 and above
by: Jing Wang, et al.
Published: (2017-01-01)

DETERMINATION OF THE RABIES VIRUS-INFECTED VERO LINE CELL PORTION BY FLOW CYTOMETRY
by: A. L. Kravtsov, et al.
Published: (2019-08-01)

A phase 3 clinical trial on the immunogenicity and safety of booster vaccination after Zagreb or Essen regimens
by: Hua-Kun Lv, et al.
Published: (2025-02-01)

Study on immune persistence of the CTN-1V strain rabies vaccine in humans
by: Lidong Wang, et al.
Published: (2024-03-01)

Post-exposure prophylaxis (PEP) for rabies with purified chick embryo cell vaccine: a systematic literature review and meta-analysis
by: Scott Preiss, et al.
Published: (2018-06-01)

Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects
by: Nianmin Shi, et al.
Published: (2017-06-01)

Rabies post-exposure prophylaxis for a male with severe Henoch Schönlein purpura following rabies vaccination
by: Zheng-Gang Zhu, et al.
Published: (2018-11-01)

Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposureResearch in context
by: Gagandeep Kang, et al.
Published: (2023-07-01)

Evaluation of the Efficacy of the Vaccine Production Process in Removing Residual Host Cell DNA from the Vero Cell Rabies Vaccine
by: Jia Li, et al.
Published: (2024-12-01)

Infection and Prevention of Rabies Viruses
by: Shiu-Jau Chen, et al.
Published: (2025-02-01)

Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children
by: Pornthep Chanthavanich, et al.
Published: (2018-04-01)

A Randomized, Double-Blind, Controlled Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of a Lyophilized Human Rabies Vaccine (Vero Cells) in Healthy Participants Aged 10–60 Years Following Essen and Zagreb Vaccination Procedures
by: Xiaohong Wu, et al.
Published: (2023-08-01)

Development of mRNA rabies vaccines
by: Zixin Fang, et al.
Published: (2024-12-01)

Purified Vero Cell Rabies Vaccine (PVRV, Verorab<sup>®</sup>): A Systematic Review of Intradermal Use Between 1985 and 2019
by: Thomas Moulenat, et al.
Published: (2020-03-01)

Safety, immunogenicity and immune-persistence of a lyophilized human rabies vaccine (Vero cells) under Zagreb and Essen regimens: a randomized, open-label, controlled phase III clinical trial in healthy participants aged 10–60 years in China
by: Zhenzhen Liang, et al.
Published: (2024-11-01)

Safety, immunogenicity of lyophilized purified vero cell cultured rabies vaccine administered in Zagreb and Essen regimen in post-exposure subjects: A post-marketing, parallel control clinical trial
by: Lei Zhang, et al.
Published: (2021-08-01)

A STUDY OF THE ULTRASTRUCTURE OF THE SURFACE OF THE TRANSPLANTABLE LINE VERO CELLS INFECTED WITH THE RABIES VIRUS (RABV, LISSAVIRUS, RHABDOVIRIDAE)
by: S. V. Generalov, et al.
Published: (2017-10-01)

Pre-marketing immunogenicity and safety of a lyophilized purified human diploid cell rabies vaccine produced from microcarrier cultures: a randomized clinical trial
by: Xingyu Zhou, et al.
Published: (2019-04-01)

Immunogenicity and safety of purified vero cell-cultured rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in the healthy Chinese subjects: a randomized, double-blind, positive controlled phase 3 clinical trial
by: Heng Shen, et al.
Published: (2021-02-01)

Rabies and rabies immunobiological preparations: vaccinations Pasteur to the contemporary biotechnology
by: E. G. Abramova, et al.
Published: (2019-11-01)

Efficacy of Purified Vero Cell Rabies Vaccine (PVRV) under the Zagreb Regimen in Iran
by: Pooneh Rahimi, et al.
Published: (2014-08-01)

Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10–50 years old: Randomized, blinded, parallel controlled phase III clinical study
by: Xiaoyuan Huang, et al.
Published: (2023-01-01)

Management of rabies
by: J. Weyer, et al.
Published: (2019-07-01)

Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against reindeer rabies
by: Irina Matveeva, et al.
Published: (2022-09-01)

The Formation of the Eastern Africa Rabies Network: A Sub-Regional Approach to Rabies Elimination
by: Emily G Pieracci, et al.
Published: (2017-07-01)

Atypical rabies encephalitis in a six-year-old boy: clinical, radiological, and laboratory findings
by: Sunil Karande, et al.
Published: (2015-07-01)

A case of human rabies in the Urban Area of Ribeirão Preto, SP, Brazil
by: SILVA Jorgete M., et al.
Published: (1997-01-01)

Factors related to vaccines for both patients exposed with rabies and dogs
by: Lam Quy Ngo, et al.
Published: (2022-03-01)

Factors related to vaccines for both patients exposed with rabies and dogs
by: Lam Quy Ngo, et al.
Published: (2022-03-01)

MANAJEMEN INFEKSI RABIES BERISIKO TINGGI: STUDI KASUS TANPA SERUM ANTI-RABIES
by: Mahdika Ambarwaty, et al.
Published: (2023-12-01)

Amino Acid Mutation in Position 349 of Glycoprotein Affect the Pathogenicity of Rabies Virus
by: Jun Luo, et al.
Published: (2020-04-01)

Comparison of the immunogenicity and safety of the purified chick embryo cell rabies vaccine manufactured in India and Germany: A randomized, single blind, multicentre, phase IV clinical study
by: Gadey Sampath, et al.
Published: (2017-07-01)

Letter to the editor: Safety and immunogenicity of a novel recombinant rabies vaccine
by: Anurag Agarwal, et al.
Published: (2022-11-01)

Rabies virus monitoring in bat populations in Rondônia state, Brazil
by: Marilene Fernandes de Almeida, et al.

Antibody persistence upto 5 years after primary immunization and booster with an inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children
by: Weerawan Hattasingh, et al.
Published: (2022-01-01)

Analysis of determination of rabies virus neutralizing antibody titres in the sera of vaccinated humans
by: A. Yu. Butirskiy, et al.
Published: (2019-12-01)

Immunogenicity and safety of human diploid cell vaccine (HDCV) vs. purified Vero cell vaccine (PVRV) vs. purified chick embryo cell vaccine (PCECV) used in post-exposure prophylaxis: a systematic review and meta-analysis
by: Shi-Yuan Wang, et al.
Published: (2022-01-01)